In gene function research, gene silencing has become an essential tool for investigating the roles of specific genes. As a core delivery platform for RNA interference (RNAi), shRNA plasmids enable sustained intracellular expression of short hairpin RNA (shRNA), providing long-term suppression of target gene expression. However, conventional shRNA plasmids may be associated with variable knockdown efficiency and limited durability, creating challenges for researchers conducting loss-of-function studies.
Miaoling Biotechnology Co., Ltd., a specialized provider of life science research tools, has developed a comprehensive shRNA gene silencing portfolio supported by an extensive inventory of more than 100,000 ready-to-ship plasmids. The portfolio covers multiple delivery platforms and research applications, combining conventional plasmid-mediated approaches with lentiviral and inducible gene silencing technologies to support applications ranging from transient knockdown to stable gene suppression.
Technical Platform: Flexible Gene Silencing Across Multiple Systems
Miaoling's gene silencing plasmid portfolio uses a modular design centered on U6 promoter-driven shRNA expression. The platform includes three major technology options:
Plasmid-Based Gene Silencing
Classic vectors such as pCDH-U6-shRNA-EF1-Puro and pLKO.1-Puro support rapid gene function validation through transient transfection. These vectors incorporate a puromycin (Puro) selection marker for enrichment of transfected cells, while the U6 promoter enables efficient transcription of shRNA.
Lentiviral Gene Silencing
For difficult-to-transfect cell types, including primary cells, neurons, and stem cells, Miaoling provides integrated lentiviral vectors such as P29436 pLV3-U6-MCS-shRNA-CopGFP-Puro. The vector incorporates a third-generation self-inactivating (SIN) design and is suitable for efficient gene delivery in cell systems where conventional transfection methods may be less effective.
Inducible Gene Silencing
By incorporating Tet-On or doxycycline (Dox)-inducible elements, inducible systems allow researchers to control the timing of gene silencing. This approach is particularly useful for studying gene function at different developmental stages or during disease progression.
This multi-platform architecture provides researchers with greater flexibility than a single delivery strategy. For example, plasmid-mediated transient transfection can be used for rapid assessment of target protein expression, while lentiviral delivery can support long-term studies requiring stable gene suppression.
Product Advantages: Quality Control from Design to Validation
Miaoling has established a comprehensive quality-control workflow for shRNA plasmid development and production. All vectors undergo sequence verification, with sequence fidelity confirmed to ensure accurate shRNA target design.
At the production stage, automated instrumentation is used for high-purity, low-endotoxin plasmid preparation. Endotoxin levels are controlled at <0.1 EU/μg, while the supercoiled fraction is maintained at ≥85% to support downstream transfection applications.
Miaoling also offers a broad range of functional element configurations. For example, the pLV3 series incorporates functional elements such as WPRE and CopGFP, allowing researchers to monitor transduction using fluorescence-based methods. For experiments requiring stable selection, vectors are available with multiple antibiotic resistance markers, including Neo, Puro, and Hygro, providing compatibility with different cell selection systems.
Applications: From Basic Research to Preclinical Studies
shRNA plasmids are particularly valuable in cancer gene function research. By establishing stable cell lines with shRNA-mediated suppression of specific oncogenes, researchers can systematically investigate the effects of target gene knockdown on phenotypes such as cell proliferation, migration, and invasion.
Miaoling provides shRNA vector systems such as pLV3-U6-RUVBL1AS1, supporting targeted gene silencing strategies for functional studies. Multiple shRNA designs can also be evaluated to improve confidence in target-specific phenotypic effects and help reduce concerns about off-target activity.
In signaling pathway research, shRNA plasmids can be combined with promoter reporter systems. Miaoling's pMCS-FLuc-SV40-hRluc-Neo dual-luciferase reporter system integrates firefly luciferase as the reporter gene and Renilla luciferase as the internal control within a single vector. This configuration enables quantitative analysis of changes in promoter activity following gene silencing while helping normalize experimental variation.
For research projects requiring in vivo validation, Miaoling also offers ready-to-use lentiviral products. These viral preparations undergo endotoxin removal and titer testing and can be used in appropriately designed animal studies, including mouse tail-vein administration or localized delivery, reducing the need for researchers to perform viral packaging in-house.
End-to-End Services: From Vector Construction to Technical Support
Miaoling provides an integrated technical service workflow for shRNA plasmid construction. Researchers can request custom shRNA target sequences based on their experimental requirements. For DNA fragments up to 1,000 bp, delivery can be completed within one week.
The service workflow includes target design, vector cloning, sequence verification, and functional prediction, helping simplify the technical requirements associated with shRNA construct development.
For lentiviral packaging, Miaoling provides high-titer viral preparations with a target titer of ≥1 × 10⁸ TU/mL, with typical delivery timelines of 2–4 weeks.
For large-scale research applications, Miaoling's plasmid preparation services support production from milligram to gram quantities. Automated purification systems are used to maintain batch-to-batch consistency, making the service suitable for applications such as biopharmaceutical R&D, gene therapy research, and plasmid-based vaccine development.
Market Reach and Research Community Adoption
Miaoling currently serves more than 6,000 research organizations nationwide, including major universities and research institutions throughout China. According to company data, Miaoling generated RMB 34 million in revenue in 2025, representing a 30.8% increase from 2024, and completed delivery of nearly 120,000 plasmids across approximately 60,000 orders during the year.
Miaoling Biotechnology has earned broad recognition for its competitive pricing, high sequencing accuracy, and short turnaround times. For standard custom orders, the turnaround time has been reduced from 7 business days to just 5, while ready-to-ship products are typically dispatched within 8 hours. This level of delivery efficiency is among the faster turnaround times in the life science research tools industry.
Supporting More Standardized Gene Function Research
As a fundamental tool for loss-of-function studies, standardized and scalable shRNA plasmid technologies can help improve the efficiency and reproducibility of gene function research. By maintaining a large ready-to-ship inventory and scalable production capabilities, Miaoling aims to reduce the time and logistical barriers associated with obtaining high-quality gene silencing plasmids.
From a technology development perspective, shRNA plasmid systems continue to evolve toward greater specificity, reduced cytotoxicity, and more precise control of gene expression. Supported by a 4,000 m² laboratory facility, P2-level laboratory infrastructure, and an R&D team in which more than 50% of personnel hold master's or doctoral degrees, Miaoling continues to expand and refine its product portfolio.
The company holds two invention patents and more than 20 utility model patents, providing intellectual property support for ongoing product and technology development.
For researchers conducting gene function studies, selecting well-characterized shRNA plasmids with appropriate quality controls and technical support can help streamline experimental workflows and reduce avoidable construct-development challenges. By integrating ready-to-ship plasmids, custom construction services, and technical support, Miaoling provides an end-to-end platform for researchers applying gene silencing technologies across a broad range of life science research applications.
https://www.miaolingbio.net
Wuhan MiaoLing Biotechnology Co., Ltd.